Izabella O.
- Country
- Denmark
- Department
- Department of Neurology
Research Overview
- Evaluation of Nipocalimab Efficacy and Safety in Adults with Seropositive Generalized Myasthenia Gravis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Gefurulimab (ALXN1720) Efficacy and Safety in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Subcutaneous Versus Intravenous Human Normal Immunoglobulin in Treatment-Naïve Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Data & Insights
Has run more than one trial at 19 of 95 partner sites.
Specializations
Neuromuscular Disorders
The investigator specializes in treating generalized myasthenia gravis (gMG), focusing on novel therapeutic approaches for patients with autoantibodies against acetylcholine receptor (AChR).
- Complement Inhibition Therapy
- Antibody-Based Treatments
- Daily Function Assessment
Their research encompasses evaluation of various treatment modalities including monotherapy and combination approaches for gMG management.
Motor Neuron Disease
The investigator conducts research in amyotrophic lateral sclerosis (ALS), with particular attention to ventilation-free survival and functional outcomes in patients.
- Respiratory Function
- Disease Progression Markers
- Quality of Life Measures
Their work focuses on evaluating innovative therapeutic interventions for ALS management.
Peripheral Neuropathies
The investigator studies chronic inflammatory demyelinating polyneuropathy (CIDP), examining various immunoglobulin administration routes and their therapeutic efficacy.
- Immunoglobulin Therapy
- Treatment Response Assessment
- Long-term Disease Management
Their research explores comparative effectiveness of different immunoglobulin delivery methods in newly diagnosed CIDP patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.